Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines

Paired sera from 20 patients with acute mumps infection, 16 from persons vaccinated with live attenuated mumps virus vaccine, and 12 from persons vaccinated with formalin-inactivated virus vaccine were studied for mumps antibodies by single radial hemolysis (SRH), hemagglutination inhibition (HI), and by enzyme immunoassays (EIA) specific for whole virus, envelope glycoprotein, and nucleocapsid antibodies. Mumps patients had diagnostic rises in serum mumps antibodies in 90–100% of the cases depending on the method of assay. Vaccination resulted in seroconversion in 75–88% (live vaccine) and in 92% (inactivated vaccine) of the cases as detected by SRH or EIAs, whereas HI detected seroconversion only in 38% and 58% of the cases, respectively. Immunoprecipitation analyses revealed that all sera from mumps patients and nearly all postvaccination sera had antibodies against the main structural proteins of mumps virus. By immunoblotting, antibodies against denatured hemagglutinin-neuraminidase (HN) and fusion protein (F) were detected in 15–25 % of mumps patients and persons vaccinated with live vaccine, whereas most postvaccination sera from those vaccinated with inactivated vaccine had HN (92%) and F (83%) protein antibodies, suggesting that antibodies against the denatured form of proteins are formed.     

Effectiveness of annual booster inoculations against various influenza serotypes and the procedure for mass vaccination

The epidemiological observation during an outbreak of A (H3N2) influenza in February-March, 1983, showed that the third annual vaccination with killed influenza vaccine did not enhance the effectiveness of vaccinations in the populations under study. It was observed that 14 months after immunization, 55.9% of the subjects examined had antibody titres of 1:40 or higher to the A/Bangkok/1/79 strain antigenically related to the vaccine strain, and 41% of the subjects of this group had antibodies to the subsequent drift variant of influenza A (H3N2) virus. These values were significantly higher than those in the group of subjects given no influenza vaccine. It is suggested that after 2 years of vaccination with killed influenza vaccines with the maximum coverage of the entire population, vaccinations be given alternately to half of previously vaccinated subjects with a 2-year interval up to the emergence of a new shift variant of influenza A virus, when again vaccination of the entire population for two successive years will be required.     

Genetic vaccination against tuberculosis

New weapons are needed in the fight against tuberculosis. Recent research indicates that a vaccine better than BCG may be within reach. A diverse range of protein antigens can give encouragingly high levels of protective immunity in animal models when administered with adjuvants or as DNA vaccines. Accelerated arrest of bacterial multiplication followed by sustained decline in bacterial numbers are key parameters of protection and so the vaccine must target antigens produced by both actively multiplying and growth-inhibited bacteria. Consistent with this, the protective antigens have been found among secreted and stress proteins (e.g. Ag85, ESAT-6, hsp65, hsp70). Species-specific antigens are not needed, hence these remain available for diagnostic tests. Adoptive transfer of protection from vaccinated or infected mice into naive mice by transfer of purified T cells and clones shows that protection is expressed by antigen-specific cytotoxic T cells that produce interferon- and lyse infected macrophages. These cells are produced in response to endogenous antigen. DNA vaccination appears to be an excellent way of generating these cells and may be able to give long-lasting protection.     

Avidity of IgG antibodies against mumps, parainfluenza 2 and Newcastle disease viruses after mumps infection

Paired serum samples from 39 patients with recent mumps infection were assayed for IgG antibodies against mumps, parainfluenza 2 and Newcastle disease virus (NDV). A modified enzyme immunoassay was used, giving separate estimates of high avidity antibodies (EHAA) and total specific antibodies (ETSA). A marked cross-reaction was seen between mumps and parainfluenza 2 virus, with changes of ETSA between paired samples of about the same magnitude against both these viruses. The mean change of EHAA against mumps was, however, significantly greater than that against parainfluenza 2. There were 16 patients who had a change of ETSA greater against parainfluenza 2 than against mumps. When the EHAA responses were compared, there were only 8 such patients. The responses against NDV were negligible. Estimation of antibody avidity, even by the arbitrary method used, can distinguish between homotypic and cross-reactive heterotypic antibodies after mumps infection. The implications for expressing the results of enzyme immunoassay are discussed.     

Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps

Mumps virus infection is a potentially serious viral infection of childhood and early adulthood. In China, live, attenuated S(79) mumps virus vaccine has been licensed for pediatric use since 1990. There has been no assessment of its efficacy. Thus, the objective of this study was to determine the effectiveness of live, attenuated S(79) mumps virus vaccine against clinical mumps. Cases were selected from the China Information System for Disease Control and Prevention during September 2004 to March 2005. Each case was matched to a control by gender, age, and area of residency. In all, 469 cases and 469 controls were enrolled in the study. Vaccination information was obtained from the Children's EPI Administrative Computerized System. Vaccine effectiveness (VE) was calculated for one or two doses of S(79) vaccine, with 95% confidence intervals (CI). VE of mumps virus vaccine for one dose versus none was protection of 86.0% (95% CI, 77.2% to 91.5%) of recipients, and VE was much higher in the first 4 years than in the 5 to 12 years after vaccination. The S(79) vaccine can effectively prevent clinical mumps, and a second dose of mumps virus vaccine is necessary for the protection of children in China.     

Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic

We evaluated the impact of a nurse program for hepatitis B virus vaccination in a center from the Swiss HIV Cohort Study. Immunity (anti-HBs >10 IU/mL) increased from 32% to 76% in the intervention center (n = 238) where vaccine management was endorsed by nurses, but only from 33% to 39% in control centers (n = 2712, P < 0.001) where management remained in charge of physicians. Immunity against HBV in the HIV population is insufficient in Switzerland. Specific nurse vaccination program may efficiently improve health care.     

Dendritic-cell-based therapeutic vaccination against cancer

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions. Current studies aim to improve the DC vaccine approach and capture the potential of these cells in order to gain access to lymphoid tissues and induce strong cell-mediated immunity. DC clinical trials are moving towards a more professional environment, in accordance with the latest quality standards. This explains the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity.     

Field vaccination of broilers against coccidiosis

Control of coccidiosis by vaccination or by medication with anti-coccidial drugs were compared on a commercial broiler farm. An attenuated, embryo-adapted line of Eimeria tenella, a virulent laboratory strain of E. acervulina and a precocious (attenuated) line of E. maxima, used for vaccination, were given in three combinations: E. tenella alone, E. tenella plus E. acervulina or E. tenella together with E. acervulina and E. maxima. Oocysts were given via feed when chickens were 2 to 8 days old. In four trials the performance of 8,416 chickens vaccinated with E. tenella alone or in combination with E. acervulina was as that of chickens given anticoccidial drugs. The performance of 3,601 chickens vaccinated with E. tenella, E. acervulina and E. maxima was not better than that of chickens vaccinated with E. tenella and E. acervulina only. The performance of 61,772 chickens vaccinated with E. tenella and E. acervulina in four large scale crops was similar to that of the control chickens and that of the previous six crops, which had been medicated with anticoccidial drugs.